TScan’s Alloha Phase 1 Heme Trial Shows Positive Data
Relapse-free survival favored TSC-101 over standard transplant alone in the Phase 1 ALLOHA study with a hazard ratio of...
BioNTech’s Gotistobart Shows Survival Benefit in Lung Cancer
In the non-pivotal, dose-confirmation stage of the randomized Phase 3 PRESERVE-003 trial in metastatic squamous NSCLC after PD-(L)1 therapy...
Legend Biotech: New Myeloma, Lymphoma CAR-T Data at ASH
Topline data: In triple-class–exposed multiple myeloma patients with three prior lines of therapy from CARTITUDE-1, a single infusion of...
Prelude Therapeutics Presents MPN Program Data at ASH 2025
Preclinical data presented at ASH showed that Prelude Therapeutics’ JAK2V617F-selective JH2 inhibitor PRT12396 inhibited mutant JAK2 signaling while preserving...
EpiEndo’s Pioneering EP395 Clinical Trial for COPD Patients
In a 12-week, randomized, double-blind, placebo-controlled study in stable COPD, EP395 (glasmacinal) reduced sputum neutrophilic inflammation versus placebo, was...
Promising Lisaftoclax Data Offers New Hope at ASH 2025
In a Phase Ib/II study of 103 patients with myeloid malignancies, lisaftoclax plus azacitidine delivered an overall response rate...
Ascentage Presents Pivotal Lisaftoclax Data at ASH Meeting
In a registrational Phase II study of 77 patients with BTK inhibitor–refractory relapsed/refractory CLL/SLL, lisaftoclax monotherapy delivered a 62.5%...
Nurix Data Shows Durable, Deepening Response in CLL Trial
Objective response rate of 83% with two complete responses and a median progression-free survival of 22.1 months were reported...
Arvinas Data: ARV-393 & Glofitamab Show Synergy, Activity
In a humanized high-grade B‑cell lymphoma xenograft model, ARV‑393 combined with glofitamab delivered 81% tumor growth inhibition with concomitant...
Beam’s Risto-Cel Shows Durable Profile in Sickle Cell Trial
In updated Phase 1/2 data from 31 sickle cell disease patients treated with ristoglogene autogetemcel (risto-cel; formerly BEAM-101), mean...